Astellas Pharma Europe Ltd. has announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of enzalutamide in chemotherapy-naive metastatic CRPC. The data were presented during a plenary session at the 2015 European Association of Urology (EAU) Congress in Madrid, Spain.
“The late breaking data presented at this year’s EAU Congress further demonstrate the breadth and depth of the enzalutamide development programme,” said Claire Thom, Pharm.D., Senior Vice President and Oncology Therapeutic Head, Astellas Pharma Global Development, Inc. We are encouraged to see that enzalutamide continues to generate promising data for men with advanced prostate cancer and their loved ones. For more information please visit MNT Website
